Foreign investors net sell RM196.2mil in equities on Bursa Malaysia


KUALA LUMPUR: Foreign investors reverted to a selling stance, net offloading RM196.2mil worth of equities on Bursa Malaysia, according to MIDF Research.

The research house noted that foreign investors only net bought on Monday and Tuesday, with purchases of RM39.1mil and RM107.6milrespectively, but net sold from Wednesday to Friday.

The largest net outflow occurred on Thursday, amounting to RM230.3mil.

“The sectors that recorded the highest net foreign inflows were construction (RM86.5mil), financial services (RM85.7mil) and healthcare (RM53mil.

“Sectors with the highest net foreign outflows were utilities (-RM266.9mil), technology (-RM50.9mil), and telecommunications & media (-RM45.7mil),” MIDF said in its weekly fund flow report.

Local institutional investors net bought RM244.6mil in equities on Bursa Malaysia last week, following a brief period of net selling the week before.

Meanwhile, local retail investors continued to net sell equities, totalling RM48.4mil last week.

The average daily trading volume (ADTV) declined by 19.6% among foreign investors, while local retail and institutional investors saw increases of 2.2% and 1.8%, respectively.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Bursa Malaysia , MIDF , fund flow

   

Next In Business News

Malaysia’s capital market hits RM4 trillion milestone, driven by strong domestic growth and IPO surge
TopVision makes ACE Market debut with 18% premium
China November industrial output rises 5.4%, above expectations
Foreign investors extend Bursa Malaysia sell-off with RM882.4mil outflow
Bitcoin surges above US$106,000 on strategic reserve hopes
Ringgit up marginally against US dollar in early trade
FBM KLCI inches up in early trade; TopVision shines in debut
Trading ideas: Axiata, Yinson, Datasonic, Exsim Hospitality, Lotte Chemical Titan, T7
Experts see big expansionary moves ahead by China’s government
MicroStrategy, Palantir added to Nasdaq 100, with Moderna facing an exit

Others Also Read